SHANGHAI — On April 21, 2023, OBiO Technology (Shanghai) Corp., Ltd. (“OBiO” or “the Company”), a leading gene and cell therapy CDMO in China, announced the launching of a new GMP manufacturing base, named OBiO Intelli-M. The new base was located in the China (Shanghai) Pilot Free Trade Zone, Lin-Gang Special Area, with 29 production lines and 828,000+ square feet in area, which was one of the biggest super factories for gene therapy in the world. [Read more…]
Stem Genomics opens a local branch partnering with KaryoLogic to bring digital PCR and karyotyping services to North American clients
April 20, 2023 – Stem Genomics, a French biotech company specializing in innovative testing solutions for the quality control of stem cells for research and therapy, announces the opening of a US branch in the North Carolina Research Triangle region in a new partnership with global karyotyping expert, KaryoLogic Inc. The aim is to bring improved services for assessing the genomic integrity of human pluripotent stem cells (hPSC) to North American-based research scientists. [Read more…]
Gamida Cell Secures World’s 1st FDA Approval for an Expanded Cord Blood Cell Therapy
The FDA has approved Gamida Cell’s allogeneic cord blood cell therapy (Omisirge, formerly Omidubicel and NiCord) as a means to speed the recovery of white blood cells in cancer patients.
The approval is for a single intravenous dose of stem cells from a donor’s expanded umbilical cord blood that is processed and cultured with nicotinamide (a form of vitamin B3).
Omisirge produces faster neutrophil recovery and reduced infections compared to standard cord blood. The approval is based on a study of 125 subjects with blood cancer.Â
ImmuneBridge Raises $12M from M Ventures and Insight Partners to Advance Cord Blood-Derived NK Cell Immunotherapies
Biotech company taps into human diversity for next-generation NK cell therapies
SAN FRANCISCO–ImmuneBridge, a biotechnology company using nature’s innate intelligence to fight cancer, today announced the close of an oversubscribed $12 million seed financing co-led by global investors Insight Partners and M Ventures, the strategic, corporate venture capital arm of Merck KGaA, Darmstadt, Germany. One Way Ventures and Gaingels also participated. Cheryl Zimberlin, Investment Director at M Ventures, and Dylan Morris, Managing Director at Insight Partners have joined ImmuneBridge’s Board of Directors. [Read more…]
Dr. Robert Hariri on Cell Therapeutics, Combination Therapies, and COVID-19
With greater than 30 million cases and 946,000 deaths reported from COVID-19 worldwide, the novel Coronavirus represents one of the largest pandemics in modern history. Thankfully, it also represents the largest cooperative effort in human history.
Globally, scientists are exploring every potential weapon to suppress the threat, including vaccines, repurposed drugs, combination therapies, and as we explore here, cellular therapies with promising cell types such as natural killer (NK) cells and mesenchymal stem cells (MSCs).
In this interview with Dr. Robert Hariri, CEO of Celularity, Inc., we discuss the company’s cell therapeutics pipeline against COVID-19. Enjoy! [Read more…]
- « Previous Page
- 1
- …
- 119
- 120
- 121
- 122
- 123
- …
- 334
- Next Page »